Conjugate Vaccine Global Market Report 2025

Global Conjugate Vaccine Market Report 2024

Conjugate Vaccine Global Market Report 2025 – By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine), By Pathogen (Bacterial, Viral), By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid), By Patient (Pediatric, Adults), By End-User (Hospitals, Clinics, Homecare Settings, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

Name: Conjugate Vaccine Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Conjugate Vaccine Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Conjugate Vaccine Global Market Report 2025

Proud Members Of

Conjugate Vaccine Market Definition

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen.

The main types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines are vaccines that contain a single conjugated antigen, typically targeting a specific pathogen or strain, and are used to prevent infections caused by bacteria that have a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. They are developed with such Bacterial and Viral pathogens for the treatment of various diseases, including pneumococcal, influenza, meningococcal, and typhoid, for pediatric and adult patients used by hospitals, clinics, homecare settings, and others.

Conjugate Vaccine Market Segmentation

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Conjugate Vaccine Market Size and growth rate 2025 to 2029: Graph

Conjugate Vaccine Market Size 2025 And Growth Rate

The conjugate vaccine market size has grown rapidly in recent years. It will grow from$18.9 billion in 2024 to $21.46 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends

Conjugate Vaccine Market Growth Forecast

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $34.59 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity.

Book your 30 minutes free consultation with our research experts

Conjugate Vaccine Market Driver: The Surge In Conjugate Vaccine Use Drives Market Expansion

The increase in the use of conjugate vaccines for adults is expected to propel the growth of the conjugate vaccine market. Conjugate vaccines are designed to stimulate a strong immune response against bacterial capsular polysaccharides, enhancing the body's defense mechanism against bacterial infections. The use of conjugate vaccines in adults helps reduce the risk of severe illness, complications, and transmission of these bacterial diseases by stimulating a robust immune response. For instance, in June 2024, according to reports published by the UK Health Security Agency (UKHSA), a UK-based public health agency, the 12-month coverage for the '6-in-1' vaccine in the UK held steady at 91.7%. The first dose of the pneumococcal conjugate vaccine (PCV) remained at 93.7%. Rotavirus coverage saw a 0.6% increase, reaching 89.3%, while the second dose of the meningitis B vaccine (MenB2) rose by 0.1% to 91.5%. Therefore, the increase in the use of conjugate vaccines for adults is driving the growth of the conjugate vaccine market.

Conjugate Vaccine Market Driver: Rising Infectious Diseases Is Anticipated To Fuel The Growth Of The Conjugate Vaccine Market

The rising incidence of infectious diseases is expected to propel the growth of the conjugate vaccine market. Infectious diseases are disorders caused by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi, which can be transmitted, directly or indirectly, from one person to another, from animals to humans, or through the environment. Conjugate vaccines play a crucial role in preventing infectious diseases caused by certain bacteria, especially in vulnerable populations such as infants and young children. For instance, in November 2023, according to reports published by the World Health Organization (WHO), a Switzerland-based international public health agency, in 2022, around 10.6 million individuals globally were diagnosed with tuberculosis (TB), comprising 5.8 million men, 3.5 million women, and 1.3 million children. Therefore, the rising incidence of infectious diseases is driving the growth of the conjugate vaccine market.

Global Conjugate Vaccine Market Major Players

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Global Conjugate Vaccine Market Trend: Navigating The Conjugate Vaccine Market Through Cutting-Edge Solutions

Innovation in conjugate vaccines is a key trend gaining popularity in the conjugate vaccine market. Companies operating in the conjugate vaccine market are focused on developing innovative conjugate vaccines to sustain their position in the market. For instance, in June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes already covered by PREVNAR 13 and conjugates for seven additional serotypes associated with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

Global Conjugate Vaccine Market Trend: Industry Leader Embraces The Next-Generation 21-Valent Pneumococcal Conjugate Vaccines Advancements

Major companies operating in the conjugate vaccine market are focusing on developing latest conjugate vaccines such as 21-valent pneumococcal conjugate vaccine. The 21-valent pneumococcal conjugate vaccine is a type of vaccine designed to provide protection against infections caused by Streptococcus pneumoniae bacteria. For instance, in April 2022, Merck & Co., Inc., a US-based pharmaceutical company, announced the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its ‘V116’. The V116 is a 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. V116 is tailor-made to target the strains of pneumococcal bacteria responsible for causing diseases that are most commonly found in adults.

Conjugate Vaccine Market Merger And Acquisition: GSK Strengthens Vaccine Arm With Affinivax Inc. Acquisition

In August 2022, GSK, a UK-based company engaged in pharmaceutical and biotechnology products, acquired Affinivax Inc. for $2.1 billion. With this acquisition, GSK aims to build a strong portfolio of specialty medicines and vaccines and strengthen its position in advanced pneumococcal vaccines, including AFX3772. Affinivax is a US-based biotechnology company specializing in conjugate vaccine development.

Regional Analysis For The Global Conjugate Vaccine Market

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Conjugate Vaccine Market?

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Conjugate Vaccine Industry?

The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Conjugate Vaccine Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$21.46 billion
Revenue Forecast In 2034	$34.59 billion
Growth Rate	CAGR of 12.7% from 2024 to 2033
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine 2) By Pathogen: Bacterial, Viral 3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid 4) By Patient: Pediatric, Adults 5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users Subsegments: 1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines 2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Conjugate Vaccine Market Characteristics

3. Conjugate Vaccine Market Trends And Strategies

4. Conjugate Vaccine Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Conjugate Vaccine Growth Analysis And Strategic Analysis Framework

5.1. Global Conjugate Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Conjugate Vaccine Market Growth Rate Analysis

5.4. Global Conjugate Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Conjugate Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Conjugate Vaccine Total Addressable Market (TAM)

6. Conjugate Vaccine Market Segmentation

6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monovalent Conjugate Vaccines

Multivalent Conjugate Vaccine

6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Bacterial

Viral

6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pneumococcal

Influenza

Meningococcal

Typhoid

6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pediatric

Adults

6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Homecare Settings

Other End Users

6.6. Global Conjugate Vaccine Market, Sub-Segmentation Of Monovalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Single Pathogen Conjugate Vaccines

6.7. Global Conjugate Vaccine Market, Sub-Segmentation Of Multivalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Multiple Pathogen Conjugate Vaccines

Combination Conjugate Vaccines

7. Conjugate Vaccine Market Regional And Country Analysis

7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Conjugate Vaccine Market

8.1. Asia-Pacific Conjugate Vaccine Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Conjugate Vaccine Market

9.1. China Conjugate Vaccine Market Overview

9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Conjugate Vaccine Market

10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Conjugate Vaccine Market

11.1. Japan Conjugate Vaccine Market Overview

11.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Conjugate Vaccine Market

12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Conjugate Vaccine Market

13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Conjugate Vaccine Market

14.1. South Korea Conjugate Vaccine Market Overview

14.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Conjugate Vaccine Market

15.1. Western Europe Conjugate Vaccine Market Overview

15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Conjugate Vaccine Market

16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Conjugate Vaccine Market

17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Conjugate Vaccine Market

18.1. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Conjugate Vaccine Market

19.1. Italy Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Conjugate Vaccine Market

20.1. Spain Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Conjugate Vaccine Market

21.1. Eastern Europe Conjugate Vaccine Market Overview

21.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Conjugate Vaccine Market

22.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Conjugate Vaccine Market

23.1. North America Conjugate Vaccine Market Overview

23.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Conjugate Vaccine Market

24.1. USA Conjugate Vaccine Market Overview

24.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Conjugate Vaccine Market

25.1. Canada Conjugate Vaccine Market Overview

25.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Conjugate Vaccine Market

26.1. South America Conjugate Vaccine Market Overview

26.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Conjugate Vaccine Market

27.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Conjugate Vaccine Market

28.1. Middle East Conjugate Vaccine Market Overview

28.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Conjugate Vaccine Market

29.1. Africa Conjugate Vaccine Market Overview

29.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Conjugate Vaccine Market Competitive Landscape And Company Profiles

30.1. Conjugate Vaccine Market Competitive Landscape

30.2. Conjugate Vaccine Market Company Profiles

30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bharat Biotech International Limited Overview, Products and Services, Strategy and Financial Analysis

31. Conjugate Vaccine Market Other Major And Innovative Companies

31.1. Serum Institute of India Private Limited

31.2. Biological E. Limited

31.3. Bavarian Nordic A/S

31.4. CSL Limited

31.5. Novartis AG

31.6. GreenSignal Bio Pharma Limited

31.7. Taj Pharmaceuticals Limited

31.8. Vaxcyte Inc.

31.9. Neuron Biotech Co. Ltd.

31.10. Bio-Med Pvt. Ltd.

31.11. Sinovac Biotech Ltd.

31.12. Takeda Pharmaceutical Company Limited

31.13. Valneva SE

31.14. Dynavax Technologies Corporation

31.15. Emergent BioSolutions Inc.

32. Global Conjugate Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Conjugate Vaccine Market

34. Recent Developments In The Conjugate Vaccine Market

35. Conjugate Vaccine Market High Potential Countries, Segments and Strategies

35.1 Conjugate Vaccine Market In 2029 - Countries Offering Most New Opportunities

35.2 Conjugate Vaccine Market In 2029 - Segments Offering Most New Opportunities

35.3 Conjugate Vaccine Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Conjugate Vaccine Market, Sub-Segmentation Of Monovalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Conjugate Vaccine Market, Sub-Segmentation Of Multivalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Sanofi S.A. Financial Performance

Table 79: Pfizer Inc. Financial Performance

Table 80: Merck & Co. Inc. Financial Performance

Table 81: GlaxoSmithKline plc Financial Performance

Table 82: Bharat Biotech International Limited Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Conjugate Vaccine Market, Sub-Segmentation Of Monovalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Conjugate Vaccine Market, Sub-Segmentation Of Multivalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Sanofi S.A. Financial Performance

Figure 79: Pfizer Inc. Financial Performance

Figure 80: Merck & Co. Inc. Financial Performance

Figure 81: GlaxoSmithKline plc Financial Performance

Figure 82: Bharat Biotech International Limited Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the oral biologics and biosimilars market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the human microbiome therapeutics market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the oncology drugs market research report 2022 with industry size, share, segments and market growth

Cancer Vaccines Global Market Report 2025 – By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), By Cancer Type (Prostate, Cervical, Colorectal, Throat, Other Cancer Types), By End-User (Cancer Treatment Centers, Research Institutes) – Market Size, Trends, And Global Forecast 2025-2034

View Report

DTP Vaccines Global Market Report 2025 – By Product type (DTaP, TD, Tdap), By Disease (Diphtheria, Pertussis, Tetanus), By End-User (Hospitals, Clinics, Vaccination Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Companion Animal Veterinary Vaccines Global Market Report 2025 – By Product (Inactivated, Live Attenuated, Recombinant, Other Products), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pediatric Vaccine Global Market Report 2025 – By Vaccine Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies), By Application (Infectious Disease, Allergy, Cancer) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Veterinary Vaccines Global Market Report 2025 – By Application (Livestock Vaccines, Companion Animal Vaccines), By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Vaccine Types), By Disease Type (Anaplasmosis, Canine Parvovirus, Foot And Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive And Respiratory Syndrome (PRRS)) – Market Size, Trends, And Global Forecast 2025-2034

View Report

H1N1 Vaccine Global Market Report 2025 – By Product Type( Inactivated Vaccine, Live Attenuated Vaccine ), By Route Of Administration( Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination ), By End Users( Hospitals, Clinics, Research and Diagnostic Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Meningococcal Vaccines Global Market Report 2025 – By Vaccine Type (Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine), By Serotype (Men Acwy, Men B/Bc, Men C), By Age Group (Infants, Children, Adolescents and Young Adults, Adults), By Distribution Channel ( (Pharmacies, Community Clinics, Public Health Agencies, Other Channels), By End user (Hospitals, Research, Academic Institutes) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Dog Vaccines Global Market Report 2025 – By Type( Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines), By Route Of Administration( Subcutaneous, Intramuscular, Intranasal), By Application( Below 6 Months, Above 6 Months) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Conjugate Vaccine market?

How will the Conjugate Vaccine market drivers and restraints affect the market dynamics? What forces will shape the Conjugate Vaccine industry going forward?

The Conjugate Vaccine market major growth driver - The Surge In Conjugate Vaccine Use Drives Market Expansion. For further insights on the Conjugate Vaccine market, request a sample here

What is the forecast market size or the forecast market value of the Conjugate Vaccine market?

The Conjugate Vaccine market size has grown strongly in recent years. The conjugate vaccine market size has grown rapidly in recent years. It will grow from$18.9 billion in 2024 to $21.46 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $34.59 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity. For further insights on the Conjugate Vaccine market, request a sample here

How is the Conjugate Vaccine market segmented?

The conjugate vaccine market covered in this report is segmented –
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users Subsegments:
1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines
2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines For further insights on the Conjugate Vaccine market, request a sample here

Which region has the largest share of the Conjugate Vaccine market? What are the other regions covered in the report?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Conjugate Vaccine market, request a sample here.

Who are the major players in the Conjugate Vaccine market?

What are the key trends in the Conjugate Vaccine market?

Major trends in the Conjugate Vaccine market include Navigating The Conjugate Vaccine Market Through Cutting-Edge Solutions. For further insights on the Conjugate Vaccine market, request a sample here.

What are the major opportunities in the Conjugate Vaccine market? What are the strategies for the Conjugate Vaccine market?

For detailed insights on the major opportunities and strategies in the Conjugate Vaccine market, request a sample here.

How does the Conjugate Vaccine market relate to the overall economy and other similar markets?

For detailed insights on Conjugate Vaccine's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Conjugate Vaccine industry?

For detailed insights on the mergers and acquisitions in the Conjugate Vaccine industry, request a sample here.

What are the key dynamics influencing the Conjugate Vaccine market growth? SWOT analysis of the Conjugate Vaccine market.

For detailed insights on the key dynamics influencing the Conjugate Vaccine market growth and SWOT analysis of the Conjugate Vaccine industry, request a sample here.